Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining global development, manufacturing, and commercialization rights to antibody conjugate drugs (ADCs) based on the latter’s ADC technology platform, focusing on two designated, undisclosed targets. No financial details were revealed.
Medilink’s ADC Technology
Medilink Therapeutics boasts the latest-generation Tumor Microenvironment Activable LINker (TMALIN) ADC technology, which can enlarge therapeutic windows and improve therapeutic efficacy. Its drug candidates YL201 and YL202 have entered into Phase I clinical trials in China and the US.
Henlius Bio’s Portfolio and Platform
Henlius Bio, meanwhile, has 5 listed drugs in China and 1 listed overseas, with 15 indication approvals and 4 market filings under review in China. The company, focused on cancer, autoimmune diseases, eye diseases, and others, has set up an integrated biomedicine platform.-Fineline Info & Tech
